Low dose naltrexone may leads to higher induction of 5‐point endoscopic response CDEIS compared with placebo (low certainty).
Low dose naltrexone showed no clear difference in sleep disturbance (adverse event) compared with placebo (low certainty).
Low dose naltrexone showed no clear difference in withdrawals due to adverse outcomes compared with placebo (low certainty).
Anti‐cancer therapy showed no clear difference in overall survival compared with best supportive care (moderate certainty).
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus topoisomerase inhibitor compared with gemcitabine alone (high certainty).
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus taxane compared with gemcitabine alone (high certainty).
Gemcitabine combinations may leads to lower overall survival ‐ Gemcitabine plus other combinations of chemotherapy compared with gemcitabine alone (low certainty).
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus other agent(s) compared with gemcitabine alone (low certainty).
Fluoropyrimidine combinations showed no clear difference in overall survival compared with fluoropyrimidine alone (low certainty).
Various types of chemotherapy probably leads to higher overall survival ‐ 5FU compared with gemcitabine (moderate certainty).
Various types of chemotherapy probably leads to lower overall survival ‐ FOLFIRINOX compared with gemcitabine (moderate certainty).
Various types of chemotherapy leads to lower overall survival ‐ Fixed dose rate gemcitabine compared with gemcitabine (high certainty).
Various types of chemotherapy showed no clear difference in overall survival ‐ CO‐101 compared with gemcitabine (moderate certainty).
Various types of chemotherapy showed no clear difference in overall survival ‐ ZD9331 compared with gemcitabine (moderate certainty).
Various types of chemotherapy showed no clear difference in overall survival ‐ Exatecan compared with gemcitabine (moderate certainty).
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus platinum agent compared with gemcitabine alone (low certainty).
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus fluoropyrimidine compared with gemcitabine alone (high certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.